ArticleCureus2025
Added Value of Nucleic Acid Testing in Blood Banks: A 15-Year Retrospective Study from India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Viral transfusion-transmissible infections (TTIs), hepatitis B (HBV), hepatitis C (HCV), and human immunodeficiency virus (HIV) pose a major risk to blood safety in India, where most blood banks rely on serology alone for TTI screening. Our blood bank at Max Healthcare, New Delhi, India, has used nucleic acid testing (NAT) alongside serology for TTI screening since 2010. Objectives The aim of this study was to evaluate 15 years of real-world blood bank data to evaluate the impact of NAT alongside serology in improving TTI detection and transfusion safety. Methods This single-centre retrospective observational study analysed blood donor, serology, and NAT data from 211,555 donations between January 2010 and December 2024. All donations underwent chemiluminescence immunoassay (CLIA)-based serology for TTI detection. All seronegative samples were subject to NAT on the Cobas MPX polymerase chain reaction (PCR)-based minipool NAT (Roche, Basel, Switzerland). Seropositive donations and NAT-reactive donations were discarded. Results A total of 2,04,609 (96.72%) were replacement donations. A total of 3,333 (1.58%) donations were seropositive for viral TTIs, and most of these were from replacement donors (N=3,289; 98.68%). Seropositivity was highest for HBV (N=1,460; 43.78%), followed by HCV (N=1,213; 36.39%) and HIV (N=660; 19.8%). NAT detected 205 additional TTI cases missed by serology; most (N=164; 79.76%) were HBV NAT yields, followed by HCV (N=35; 16.83%) and HIV (N=7; 3.41%). There was one case of HBV-HCV co-infection. The overall NAT yield rate was 1:1005, and the HBV NAT yield rate was 1:1262. Conclusion NAT enhances blood safety by detecting infections missed by serology, supporting the need for mandatory nationwide implementation despite cost and infrastructure challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.